CompletedNCT00716755
Official study titleThe Minimal Effective Dose of Antipsychotic Medication in Older Patients With Schizophrenia: a PET Study.
This study has finished and is no longer accepting participants.
In TorontoSchizophreniaMedication studyAges 50+
- Countries
- Canada
- Sponsor
- Centre for Addiction and Mental Health (Hospital / academic medical center)
CompletedNCT01786239
Official study titleDetecting Which Patients With Schizophrenia Will Improve With Omega-3 Treatment
This study has finished and is no longer accepting participants.
In Glen OaksSchizophrenia, BipolarityMedication studyAges 15–40
- Countries
- United States
- Sponsor
- Delbert Robinson
CompletedNCT01602029
Official study titleRandomized Double Blind Placebo Controlled Study of Ondansetron and Simvastatis Added to Treatment As Usual in Patients with Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including KarachiSchizophreniaMedication studyAges 18–65
- Countries
- Pakistan
- Sponsor
- Pakistan Institute of Living and Learning
Enrolling By InvitationNCT01088386
This study is by invitation only.
In Blue BellSchizophreniaObservational studyAges 18+
- Countries
- United States
- Sponsor
- Eli Lilly and Company
TerminatedACTRN12610000244000
Official study titleThe NEURAPRO-Q (North America, EURope, Australia PROdrome) Study: A multicentre randomised controlled trial (RCT) to evaluate the effect of Quetiapine and Cognitive-Behavioural Case Management on the incidence of first episode psychosis in Symptomatic Patients at Ultra-High Risk for Early Progression to Schizophrenia and Other Psychotic Disorders
This study ended early.
In ChinaSchizophreniaInterventional studyAges 15–40
- Countries
- United States, China
- Sponsor
- Orygen Youth Health Research Centre
CompletedACTRN12608000461392
Official study titleClinical Trial of a Selective Estrogen Receptor Modulator (raloxifene) in the treatment of cognitive deficits and psychotic symptoms of patients with schizophrenia
This study has finished and is no longer accepting participants.
In RandwickSchizophreniaInterventional studyAges 18–55
- Countries
- Australia
- Sponsor
- University of New South Wales
CompletedACTRN12621001081808
Official study titleThe effect of cognitive remediation on reward learning in adults with schizophrenia spectrum disorder
This study has finished and is no longer accepting participants.
In WoolloongabbaSchizophreniaInterventional studyAges 18–35
- Countries
- Australia
- Sponsor
- Princess Alexandra Hospital and health service
Not recruitingISRCTN11998005
This study isn't currently recruiting.
In United KingdomSchizophreniaResearch studyAges 18+
- Countries
- United Kingdom
- Sponsor
- University of Manchester
Not recruitingISRCTN10917911
This study isn't currently recruiting.
In SpainSchizophreniaResearch studyAges 18–65
- Countries
- Spain
- Sponsor
- Complejo Hospitalario of Navarra
CompletedNCT01592110
What is this study about?This study evaluated the safety of risperidone-SABER for people with schizophrenia.
This study has finished and is no longer accepting participants.
In GlendaleSchizophreniaMedication studyAges 18+
- Countries
- United States
- Sponsor
- Zogenix, Inc.
WithdrawnNCT05956600
Official study titleAn Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Amisulpride in Treating Patients With Schizophrenia and Schizoaffective Disorder Who Have Treatment-Resistant Positive Symptoms
This study was withdrawn before enrollment.
Location not clearly listedSchizophreniaMedication studyAges 18–65
- Countries
- Sponsor
- University of California, Los Angeles
CompletedNCT04298450
Official study titleED to EPI: Using SMS (Text) Messaging to Improve the Transition From the Emergency Department to Early Psychosis Intervention for Young People With Psychosis
This study has finished and is no longer accepting participants.
In TorontoSchizophrenia, Bipolarity, ...Behavioural studyAges 16–29
- Countries
- Canada
- Sponsor
- Centre for Addiction and Mental Health (Hospital / academic medical center)